Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
4.240
+0.020 (0.47%)
At close: Dec 5, 2025
-75.09%
Market Cap34.61M
Revenue (ttm)n/a
Net Income (ttm)-17.93M
Shares Out8.16M
EPS (ttm)-4.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,475
Average Volume28,572
Open4.220
Previous Close4.220
Day's Range4.122 - 4.350
52-Week Range3.720 - 21.850
Beta0.74
RSI30.55
Earnings DateNov 14, 2025

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified apta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.